ClearNote Health

Pre-clinical

San Diego, United StatesFounded 2019clearnotehealth.com

ClearNote Health is a commercial-stage diagnostics company leveraging its unique epigenomics platform to detect high-mortality cancers early via a simple blood draw. The company's core technology measures 5-hydroxymethylcytosine (5hmC) modifications in cell-free DNA, providing a sensitive and specific signal of developing cancer. Key achievements include NYSDOH approval and CMS reimbursement for its Avantect tests, selection for the NCI's Vanguard study, and a strategic focus on pancreatic and ovarian cancers. The company is expanding its leadership and commercial footprint to drive clinical adoption.

Founded

2019

Focus

Diagnostics

AI Company Overview

Technology Platform

Proprietary epigenomics platform that detects cancer by measuring 5-hydroxymethylcytosine (5hmC) modifications in cell-free DNA, combined with machine learning algorithms to identify and classify cancer signals from a blood draw.

Funding History

Total raised: $15M

Series A$12MKhosla VenturesMar 15, 2022

Seed$3MKhosla VenturesOct 15, 2020

Opportunities

Significant growth opportunity lies in expanding the Avantect test suite to other high-mortality cancers like lung cancer, leveraging its unique 5hmC platform.

The Virtuoso platform opens a B2B revenue stream through partnerships with biopharmaceutical companies for drug development.

International distribution agreements already cover over 50 countries, providing a clear path for global expansion.

Risk Factors

Key risks include intense competition from larger, well-funded players in the multi-cancer early detection space, the ongoing challenge of securing broad and sustainable insurance reimbursement, and the need for continued large-scale clinical validation to drive widespread physician adoption.

Competitive Landscape

ClearNote Health competes with companies like GRAIL (Galleri), Exact Sciences, and Guardant Health in the liquid biopsy-based cancer detection market. Its primary differentiation is its focus on the 5-hydroxymethylcytosine (5hmC) epigenomic mark, which it claims provides a more direct and sensitive signal of active cancer biology compared to methylation or fragmentation-based approaches used by others.